$THC

Sutaria Saumya sold $27.6M of THC

Sutaria Saumya (CEO) sold 100,000 shares of TENET HEALTHCARE CORP (THC) at an average of $276.36 ($273.34–$278.90, $27.64M total) across 5 trades over 2026-08-24 to 2026-08-25.

Original reporting
SEC EDGAR · Sutaria Saumya
Published Aug 27, 2026, 12:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 27, 2026, 12:13 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$THC
Bearish
medium confidence
Mentioned
$THC
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$THCBearishLow
01

Why it matters

The CEO's $27.6M share sale may trigger short interest and price volatility.

02

Market read

First disclosure of a sizable insider sell; traders may reassess THC exposure.

03

What to watch

no 10b5‑1 plan, suggesting discretionary timing

Relevance 7/10Novelty 7/10Timing: filing disclosed on 2026‑08‑26 after market close

Background

Form 4 filing reports insider transaction for Tenet Healthcare Corp (THC).

Company-level read

Ticker impact

$THCBearishMedium confidence
Context

CEO Sutaria Saumya sold 100,000 shares for $27.6M, reducing ownership to 433,564 shares.

Expected impact

potential short-term downside pressure

Evidence & confidence

CEO sale of $27M is material for a mid‑cap biotech; market may interpret as negative.

Market effects

may raise concerns for other biotech insiders and affect sector sentiment

limited to US biotech market

low

Counterpoint

sale could be a routine liquidity event, not a confidence signal

Key entities

  • Tenet Healthcare Corp

    Biotech firm listed on Nasdaq under ticker THC

  • Sutaria Saumya

    CEO and director of Tenet Healthcare Corp

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$THCMed

Tenet Healthcare (THC) Refinances Debt On A Fair Value Story That Looks Tightly Priced

Tenet Healthcare (THC) issued $2b in 6.250% senior notes due 2034 to refinance existing debt. Its share price has risen 25.4% in 90 days and 29.7% year-to-date. The company's fair value is estimated at $260, slightly above its current price of $258.62. Management's cost-reduction efforts have lowered contract labor and certain analytics costs, but further margin expansion may be limited.

$THCMed

Can THC's Cash Flow Support Its Expanding Capital-Return Strategy?

Tenet Healthcare (THC) reported a 27.1% year-over-year increase in operating cash flow to $2.2B in H1 2026, raising its adjusted free cash flow guidance to $1.825B-$2.055B. The company spent $1.4B on share buybacks and increased its repurchase authorization by $2B. THC is balancing buybacks with growth investments, expecting $700M-$800M in capital spending. Peers UHS and HCA also reported significant buybacks and capital investments.

$THCMed

Is Tenet Healthcare Corporation (THC) A Solid Play on Expanding Ambulatory Business?

Tenet Healthcare (THC) is focusing on its ambulatory business for growth, with BMO Capital Markets noting favorable long-term trends and margins. USPI, Tenet’s ambulatory platform, reported 9.3% revenue growth in Q2. BMO initiated coverage with a Market Perform rating and $265 price target. Hedge funds increased stakes, while short interest declined. Risks include reimbursement changes and competition.

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2 Billion Debt Refinance Means For Shareholders

Tenet Healthcare (THC) completed a $2 billion private placement of senior unsecured notes due 2034 at a 6.250% coupon. Proceeds will redeem $1.5 billion of 2027 secured notes and $0.5 billion of 2028 senior notes, altering its capital structure and interest obligations. Analysts project revenues of $24.1 billion and earnings of $1.6 billion by 2029, with some seeing potential upside.

$THCMedAI 8/10

What Tenet Healthcare (THC)'s $2b Debt Refinance Means For Shareholders

Tenet Healthcare (THC) priced a $2.0 billion private placement of 6.250% senior notes due 2034, upsized from $1.5 billion, to refinance existing 2027 and 2028 debt. The refinancing replaces secured and partly secured borrowings with unsecured notes, altering the company's debt structure. Investors focus on execution, pricing, and free cash flow, with high debt and earnings declines noted as risks.